Jason M. Silversteen, DO

Our Experts

Back to all Experts
Jason M. Silversteen, DO

Jason M. Silversteen, DO

Clinical Lead, Outpatient Neurology Specialists

Expertise & Research Interests

  • Autoimmune Neurology
  • Neuromyelitis Optica Spectrum Disorder
  • Transverse Myelitis
  • Autoimmune Encepahlitis
  • MOG Antibody Disease

Education

  • DO, Lake Erie College of Osteopathic Medicine
  • BS, Biology, Arcadia University

Jason M. Silversteen, DO

Clinical Lead, Outpatient Neurology Specialists

Dr. Silversteen is a neurology specialist at ChristianaCare, where he is also director of the Comprehensive Multiple Sclerosis Center and serves as the clinical lead for the outpatient neurology specialists practice.

He is a board-certified neurologist and holds current medical licensure in Delaware. Dr. Silversteen has conducted clinical trials, delivered presentations and lectures, and authored papers on multiple sclerosis and its treatment to both students and practicing neurologists. He has also shared his expertise in the form of patient education and community service programs.

Multimedia

MS-Neuro-IMG_3325-1200x800.jpg
MS-Neuro-IMG_3493-800x533.jpg
Jason Silversteen
of 09

Experience

Downloadable Images and Links
Media Appearances

8 Ways to Ease MS Pain

2015-10-19 , Everyday Health
This is a great place to start. “You want to be sure you’re getting proper sleep, eating a healthy diet, and getting some form of exercise," says Dr. Silversteen. "You also want to be well rested — fatigue exacerbates pain...”
Selected Papers and Publications

No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice

2018-02-02 , Current Medical Research and Opinion
The impact of multiple sclerosis (MS) center type on outcomes has not been investigated. This study aimed to evaluate baseline characteristics and clinical and magnetic resonance imaging (MRI) outcomes in patients with MS receiving fingolimod over 16 months’ follow-up at private or academic centers in the USA.

Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice

2017-12-21 , CNS Drugs
‘No evidence of disease activity’ (NEDA), a composite measure of clinical and magnetic resonance imaging outcomes, provides a comprehensive assessment of disease activity, but is not extensively reported in clinical practice. NEDA-3 is defined as patients with no new/enlarged T2 or gadolinium-enhancing lesions, no relapses, and no disability progression (according to Expanded Disability Status Scale scores). NEDA-4 comprises the components of NEDA-3 and a fourth criterion of ≤ 0.4% annualized brain volume loss.
External Service and Affiliations
  • American Academy of Neurology : Member
  • American Osteopathic Association : Member
Selected Honors and Awards
  • Beaver College Distinguished Scholar Award, Beaver College Distinguished Scholar Award
  • The Posey Award at Graduate Hospital, The Posey Award at Graduate Hospital
  • Robert Schwartzman Neurology Resident of the Year Award, Robert Schwartzman Neurology Resident of the Year Award